Table 1.
Proportional hazard calculations for each of the three mismatch repair genes with significant effect on clinical outcome measured by overall survival: MLH1, PMS1 and PMS2. Cox regression was used to calculate p-values.
| Factor | Hazard ratio | Confidence interval | p-value |
|---|---|---|---|
| MLH1high | -- | -- | |
| MLH1low | 1.61 | 1.07–2.43 | 0.02* |
| PR− | -- | -- | |
| PR+ | 0.78 | 0.54–1.13 | 0.19 |
| ERBB2− | -- | -- | |
| ERBB2+ | 1.31 | 0.87–1.99 | 0.19 |
| Stage0 | -- | -- | |
| StageI | 0.47 | 0.26–0.85 | 0.01* |
| StageII | 0.87 | 0.59–1.28 | 0.48 |
| StageIII | 1.46 | 0.68–3.13 | 0.33 |
| StageIV | 2.24 | 0.31–16.48 | 0.43 |
| TP53WT | -- | -- | |
| TP53mut | 1.97 | 1.01–3.85 | 0.04* |
| PMS1high | -- | -- | |
| PMS1low | 1.37 | 1.01–1.86 | 0.04* |
| PR− | -- | -- | |
| PR+ | 0.74 | 0.54–1.02 | 0.07′ |
| ERBB2− | -- | -- | |
| ERBB2+ | 1.46 | 0.2–10.69 | 0.71 |
| Stage0 | -- | -- | |
| StageI | 0.52 | 0.33–0.83 | 0.005* |
| StageII | 0.9 | 0.63–1.29 | 0.58 |
| StageIII | 1.8 | 0.89–3.64 | 0.1′ |
| StageIV | 2.03 | 0.28–14.76 | 0.48 |
| TP53WT | -- | -- | |
| TP53mut | 1.96 | 1.07–3.57 | 0.03* |
| PMS2high | -- | -- | |
| PMS2low | 1.86 | 1.201–2.699 | 0.004* |
| PR− | -- | -- | |
| PR+ | 0.79 | 0.55–1.15 | 0.23 |
| ERBB2− | -- | -- | |
| ERBB2+ | 1.37 | 0.91–2.09 | 0.13 |
| Stage0 | -- | -- | |
| StageI | 0.5 | 0.28–0.92 | 0.03* |
| StageII | 0.94 | 0.63–1.39 | 0.76 |
| StageIII | 1.79 | 0.82–3.91 | 0.14 |
| StageIV | 2.37 | 0.32–17.43 | 0.4 |
| TP53WT | -- | -- | |
| TP53mut | 2.11 | 1.07–4.14 | 0.03* |
*
p<0.05
′
p≤0.1